Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
257M
-
Number of holders
-
1527
-
Total 13F shares, excl. options
-
236M
-
Shares change
-
+3.79M
-
Total reported value, excl. options
-
$95B
-
Value change
-
+$1.45B
-
Put/Call ratio
-
0.9
-
Number of buys
-
636
-
Number of sells
-
-762
-
Price
-
$402.70
Significant Holders of VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) as of Q4 2024
1,770 filings reported holding VRTX - VERTEX PHARMACEUTICALS INC / MA - Common Stock as of Q4 2024.
VERTEX PHARMACEUTICALS INC / MA - Common Stock (VRTX) has 1,527 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 236M shares
of 257M outstanding shares and own 91.87% of the company stock.
Largest 10 shareholders include Capital World Investors (28.3M shares), VANGUARD GROUP INC (23.3M shares), BlackRock, Inc. (21.8M shares), STATE STREET CORP (12M shares), Capital Research Global Investors (10.4M shares), FMR LLC (9.22M shares), JPMORGAN CHASE & CO (6.31M shares), WELLINGTON MANAGEMENT GROUP LLP (5.92M shares), GEODE CAPITAL MANAGEMENT, LLC (5.65M shares), and JENNISON ASSOCIATES LLC (4.32M shares).
This table shows the top 1527 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.